Search Results - Brad Shumel

Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin Accord... by Michael J. Cork, Benjamin Lockshin, Andreas Pinter, Zhen Chen, Brad Shumel, Randy Prescilla

Connect to this object online.

Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial by Jonathan Weyne, Andrew Blauvelt, Marjolein de Bruin-Weller, Errol Prens, Penny Asbell, Debra Sierka, Zhen Chen, Brad Shumel

Connect to this object online.

Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-... by Mike Bastian, Nick Freemantle, Ana B. Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot

Connect to this object online.

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis by Jonathan I. Silverberg, Eric L. Simpson, Mark Boguniewicz, Marjolein S. De Bruin-Weller, Peter Foley, Yoko Kataoka, Gaëlle Bégo-, Zhen Chen, Brad Shumel, Jingdong Chao, Ana B. Rossi

Connect to this object online.

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study by Alexa B. Kimball, Dimittri Delevry, Min Yang, Chien-Chia Chuang, Zhixiao Wang, Gaëlle Bégo-, Bruno Martins, Eric Wu, Brad Shumel, Jessie Wang, Debra Sierka, Jingdong Chao, Bruce Strober

Connect to this object online.

Efficacy of dupilumab in moderate and severe atopic dermatitis by Stephan Weidinger, Eric L. Simpson, Jonathan I. Silverberg, Jochen Schmitt, Yael A. Leshem, Norito Katoh, Zhen Chen, Haixin Zhang, Brad Shumel, Ashish Bansal, Jingdong Chao, Yufang Lu, Ana B. Rossi, Alvina Abramova

Connect to this object online.